ShivaniSrivastavaMD
Oncology • Lawrence Township, NJHematologic Oncology
Vice President, Cell Therapy Development, Bristol Myers Squibb
Dr. Srivastava is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Bristol Myers Squibb
3401 Princeton Pike
Lawrence Township, NJ 08648
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2003 - 2004
SUNY Upstate Medical UniversityResidency, Internal Medicine, 2001 - 2003
Kasturba Medical College ManipalClass of 2000
Certifications & Licensure
IN State Medical License 2008 - 2013
Clinical Trials
- Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma Start of enrollment: 2010 Oct 01
Publications & Presentations
PubMed
- 22 citationsLoss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.Rajesh L. Thangapazham, Francisco Saenz, Shilpa Katta, Ahmed A. Mohamed, Shyh-Han Tan
BMC Cancer. 2014-01-13 - 90 citationsA Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.Indu Kohaar, Gyorgy Petrovics, Shiv Srivastava
International Journal of Molecular Sciences. 2019-04-12 - 729 citationsRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo A Ascierto, Luis Matamala
The New England Journal of Medicine. 2022-01-06
Industry Relationships
- Vice President, Bristol Myers Squibb
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
